Galactosylated chitosan or chitosan derivatives are potential carriers that can effectively target anticancer drugs to improve therapeutic effects for HCC by virtue of the galactose residue specifically recognized by ASGPR. Here, ASGR1 is linked to hepatocellular carcinoma.